Somagen Signs Supply Contract for 'SalivaDirect COVID-19 Diagnostic Service' with US Park School

[Asia Economy Reporter Hyunseok Yoo] SomaGen announced on the 24th that it has signed an annual supply contract with The Park School in the United States for the saliva testing method 'SalivaDirect™ COVID-19 diagnostic service.'

The Park School was established in 1912 in Baltimore, Maryland. It is currently a private school composed of about 800 students from kindergarten to high school and over 100 faculty and staff members.

A company official stated, "This achievement follows the annual supply contract signed with FTGCare in the United States on January 13," adding, "Above all, this annual supply contract with schools, concluded in a timely manner in line with the Back-to-school Plan actively promoted by the U.S. government and education offices, holds great significance." He continued, "We plan to continuously expand the provision of SalivaDirect™ COVID-19 diagnostic services by focusing on targeting public schools and related institutions."

In addition to the COVID-19 diagnostic service, SomaGen is preparing and expanding various clinical service pipelines. A SomaGen official explained, "On the 10th, we signed a strategic business agreement with a U.S.-based AI-driven genomic analysis data platform company to expand clinical genomic analysis services," adding, "We plan to pursue a cross-marketing strategy targeting the customers each company possesses."

Along with this, SomaGen is sequentially developing clinical microbiome analysis services. In 2019, it acquired key microbiome-related assets from uBiome. Since then, it has recruited key personnel from uBiome and other experts while developing hospital-linked microbiome analysis services. Recently, it completed the development of clinical microbiome analysis services for diagnosing female diseases such as HPV and is currently undergoing a review for pre-approval by the U.S. Food and Drug Administration (FDA). The goal is to complete the FDA review within this year and introduce the new clinical microbiome analysis service to the market.

Ryan Kim, CEO of SomaGen, said, "With two annual supply contracts, the COVID-19 diagnostic service business has firmly established itself as a pillar of the clinical diagnostic service business," adding, "We are currently actively expanding a diverse clinical service pipeline, including clinical genomics and clinical microbiome analysis services." He added, "We will make this year the inaugural year for SomaGen’s full-scale entry into the clinical service market."

This content was produced with the assistance of AI translation services.